The A1 chieve study[11 (link)] was an international, open-label, prospective, non-interventional study to determine the safety and effectiveness of BIAsp 30 (NovoMix 30®, Novo Nordisk), insulin detemir (Levemir®, Novo Nordisk) and insulin aspart (NovoRapid®, Novo Nordisk), alone or in combination, in routine clinical care. In this sub-analysis, T2D patients from India who switched from basal-bolus insulin therapy or basal insulin (NPH insulin or insulin glargine) to biphasic insulin aspart 30 were included. Patients were recruited at 621 centers in India between May 2009 and December 2010. Insulin therapy was switched at the consulting physicians’ discretion and subsequent changes in dose, frequency and use of oral glucose-lowering drugs (OGLDs) were directed by the physician in routine clinical care. There were no pre-defined study procedures and all assessments were made by the physicians. This study was approved by the local ethics committee. The study drug was commercially available and prescribed in accordance with local regulations.
Novomix 30
Manufactured by Novo Nordisk
NovoMix 30 is a premixed insulin product containing 30% soluble insulin and 70% protamine-crystallized insulin. It is designed to provide both rapid- and intermediate-acting insulin components in a single injection, aiming to help manage blood glucose levels.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using novomix 30
1
Glycemic Control with Biphasic Insulin Aspart
2
BIAsp 30 Therapy in Indian T2D
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
A1chieve was a 24-week, prospective, open-label, non-interventional study conducted across four continents to examine the safety and effectiveness of BIAsp 30 (NovoMix® 30, Novo Nordisk A/S), insulin detemir (Levemir®, Novo Nordisk A/S) and insulin aspart (NovoRapid®, Novo Nordisk A/S), alone or in combination with basal insulin, in clinical practice.[10 (link)] This subgroup analysis was performed in Indian patients with T2D who changed therapy to BIAsp 30 from BHI.
Patients were recruited from 621 centers in India between May 2009 and December 2010. The decision to switch from BHI to BIAsp 30 therapy was made by the consulting physicians who also decided the dose and dosing frequency throughout the study. BIAsp 30 was available locally and was used in accordance with the locally approved label. Concomitant oral glucose-lowering drugs (OGLDs) were also permitted at the discretion of the physician.
Data were recorded in the standard case report forms from the physicians’ notes and the patients’ diaries and blood glucose meters.
Patients were recruited from 621 centers in India between May 2009 and December 2010. The decision to switch from BHI to BIAsp 30 therapy was made by the consulting physicians who also decided the dose and dosing frequency throughout the study. BIAsp 30 was available locally and was used in accordance with the locally approved label. Concomitant oral glucose-lowering drugs (OGLDs) were also permitted at the discretion of the physician.
Data were recorded in the standard case report forms from the physicians’ notes and the patients’ diaries and blood glucose meters.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!